ketoconazole has been researched along with Electrocardiogram QT Prolonged in 15 studies
1-acetyl-4-(4-{[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazine : A dioxolane that is 1,3-dioxolane which is substituted at positions 2, 2, and 4 by imidazol-1-ylmethyl, 2,4-dichlorophenyl, and [para-(4-acetylpiperazin-1-yl)phenoxy]methyl groups, respectively.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Levoketoconazole is a ketoconazole stereoisomer in development for treatment of Cushing's syndrome and has not been assessed previously in a clinical trial in patients with Cushing's syndrome." | 9.30 | Efficacy and safety of levoketoconazole in the treatment of endogenous Cushing's syndrome (SONICS): a phase 3, multicentre, open-label, single-arm trial. ( Auchus, RJ; Biller, BMK; Cohen, F; Elenkova, A; Feelders, RA; Fleseriu, M; Geer, EB; Greenman, Y; Pivonello, R; Salvatori, R; Witek, P, 2019) |
| "Levoketoconazole is a ketoconazole stereoisomer in development for treatment of Cushing's syndrome and has not been assessed previously in a clinical trial in patients with Cushing's syndrome." | 5.30 | Efficacy and safety of levoketoconazole in the treatment of endogenous Cushing's syndrome (SONICS): a phase 3, multicentre, open-label, single-arm trial. ( Auchus, RJ; Biller, BMK; Cohen, F; Elenkova, A; Feelders, RA; Fleseriu, M; Geer, EB; Greenman, Y; Pivonello, R; Salvatori, R; Witek, P, 2019) |
| "To assess the steady-state pharmacokinetic and QT(c) effects of domperidone and ketoconazole, given alone and together." | 2.77 | Pharmacokinetic interaction between domperidone and ketoconazole leads to QT prolongation in healthy volunteers: a randomized, placebo-controlled, double-blind, crossover study. ( Baisley, KJ; Boyce, MJ; Warrington, SJ, 2012) |
| "The present clinical trial was designed to evaluate the possible pharmacokinetic and electrocardiographic interactions of the gastroenteric prokinetic drug cinitapride with ketoconazole." | 2.73 | The prokinetic cinitapride has no clinically relevant pharmacokinetic interaction and effect on QT during coadministration with ketoconazole. ( Esbri, R; Golor, G; Pavesi, M; Robert, M; Roberts, D; Salvà, M; Segarra, R, 2007) |
| " The aim of this study was to assess the QT interval in patients with Cushing's disease during long-term administration of ketoconazole." | 1.43 | No Untoward Effect of Long-Term Ketoconazole Administration on Electrocardiographic QT Interval in Patients with Cushing's Disease. ( Cavagnini, F; De Martin, M; Goulene, K; Pecori Giraldi, F; Radaelli, P; Stramba-Badiale, M; Toja, PM, 2016) |
| "Latent tuberculosis infection is an important problem for solid organ transplant recipients because of the frequency of its occurrence and its potential for reactivation." | 1.39 | Use of rifabutin for the treatment of a latent tuberculosis infection in a patient after solid organ transplantation. ( Chin-Hong, PV; Hickey, MD; Quan, DJ; Roberts, JP, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (6.67) | 18.2507 |
| 2000's | 9 (60.00) | 29.6817 |
| 2010's | 5 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fleseriu, M | 1 |
| Pivonello, R | 1 |
| Elenkova, A | 1 |
| Salvatori, R | 1 |
| Auchus, RJ | 1 |
| Feelders, RA | 1 |
| Geer, EB | 1 |
| Greenman, Y | 1 |
| Witek, P | 1 |
| Cohen, F | 1 |
| Biller, BMK | 1 |
| Hickey, MD | 1 |
| Quan, DJ | 1 |
| Chin-Hong, PV | 1 |
| Roberts, JP | 1 |
| De Martin, M | 1 |
| Toja, PM | 1 |
| Goulene, K | 1 |
| Radaelli, P | 1 |
| Cavagnini, F | 1 |
| Stramba-Badiale, M | 1 |
| Pecori Giraldi, F | 1 |
| Yeung, KS | 1 |
| Meanwell, NA | 1 |
| Boyce, MJ | 1 |
| Baisley, KJ | 1 |
| Warrington, SJ | 1 |
| Potkin, SG | 1 |
| Preskorn, S | 1 |
| Hochfeld, M | 1 |
| Meng, X | 1 |
| Hamlin, RL | 1 |
| Kijtawornrat, A | 1 |
| Keene, BW | 1 |
| Hamlin, DM | 1 |
| Mok, NS | 1 |
| Lo, YK | 1 |
| Tsui, PT | 1 |
| Lam, CW | 1 |
| Darpo, B | 1 |
| Agin, M | 1 |
| Kazierad, DJ | 1 |
| Layton, G | 1 |
| Muirhead, G | 1 |
| Gray, P | 1 |
| Jorkasky, DK | 1 |
| Dumaine, R | 1 |
| Antzelevitch, C | 1 |
| Robert, M | 1 |
| Salvà, M | 1 |
| Segarra, R | 1 |
| Pavesi, M | 1 |
| Esbri, R | 1 |
| Roberts, D | 1 |
| Golor, G | 1 |
| Sarapa, N | 1 |
| Nickens, DJ | 1 |
| Raber, SR | 1 |
| Reynolds, RR | 1 |
| Amantea, MA | 1 |
| Takemasa, H | 1 |
| Nagatomo, T | 1 |
| Abe, H | 1 |
| Kawakami, K | 1 |
| Igarashi, T | 1 |
| Tsurugi, T | 1 |
| Kabashima, N | 1 |
| Tamura, M | 1 |
| Okazaki, M | 1 |
| Delisle, BP | 1 |
| January, CT | 1 |
| Otsuji, Y | 1 |
| Zimmermann, M | 1 |
| Duruz, H | 1 |
| Guinand, O | 1 |
| Broccard, O | 1 |
| Levy, P | 1 |
| Lacatis, D | 1 |
| Bloch, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| An Open Label Study to Assess the Safety and Efficacy of COR-003 (Levoketoconazole) in the Treatment of Endogenous Cushing's Syndrome[NCT01838551] | Phase 3 | 94 participants (Actual) | Interventional | 2014-08-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"The response to COR-003 is defined as mean UFC concentration ≤ULN following 6 months of maintenance phase therapy without a prior dose increase during that phase. The proportion of responders at the End of Maintenance Phase visit, following 6 months of treatment in the Maintenance Phase, for all dose groups combined was estimated using a generalized linear model with repeated measurements based on a binomial distribution with a logit link function and with region (US vs. non-US), concurrent CS medical conditions (diabetes [Yes/No], hypertension [Yes/No]), age (rounded median split based on the ITT population), sex, disease duration (years), prior CS medication (Yes/No), prior radiation therapy (Yes/No) as Baseline covariates and visit as an independent factor.~The least squares mean (LSMEAN) estimate of the UFC response after 6 months of treatment in the Maintenance Phase alongside its 95% Wald CI is presented." (NCT01838551)
Timeframe: 6 months of maintenance phase therapy without a prior dose increase during that phase
| Intervention | proportion of subjects meeting endpoint (Least Squares Mean) |
|---|---|
| Levoketoconazole All Doses | .30 |
6 trials available for ketoconazole and Electrocardiogram QT Prolonged
| Article | Year |
|---|---|
Efficacy and safety of levoketoconazole in the treatment of endogenous Cushing's syndrome (SONICS): a phase 3, multicentre, open-label, single-arm trial.
Topics: Adolescent; Adrenal Insufficiency; Adult; Aged; Alanine Transaminase; Chemical and Drug Induced Live | 2019 |
Pharmacokinetic interaction between domperidone and ketoconazole leads to QT prolongation in healthy volunteers: a randomized, placebo-controlled, double-blind, crossover study.
Topics: 14-alpha Demethylase Inhibitors; Adolescent; Adult; Analysis of Variance; Area Under Curve; Arrhythm | 2012 |
A thorough QTc study of 3 doses of iloperidone including metabolic inhibition via CYP2D6 and/or CYP3A4 and a comparison to quetiapine and ziprasidone.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhi | 2013 |
Man versus machine: is there an optimal method for QT measurements in thorough QT studies?
Topics: Adolescent; Adult; Aza Compounds; Control Groups; Cross-Over Studies; Electrocardiography; Female; F | 2006 |
The prokinetic cinitapride has no clinically relevant pharmacokinetic interaction and effect on QT during coadministration with ketoconazole.
Topics: Administration, Oral; Adult; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Benzamides; Biological | 2007 |
Ritonavir 100 mg does not cause QTc prolongation in healthy subjects: a possible role as CYP3A inhibitor in thorough QTc studies.
Topics: Adult; Aza Compounds; Cross-Over Studies; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors | 2008 |
9 other studies available for ketoconazole and Electrocardiogram QT Prolonged
| Article | Year |
|---|---|
Use of rifabutin for the treatment of a latent tuberculosis infection in a patient after solid organ transplantation.
Topics: Adolescent; Antibiotics, Antitubercular; Drug Interactions; Drug Monitoring; Drug Substitution; Drug | 2013 |
No Untoward Effect of Long-Term Ketoconazole Administration on Electrocardiographic QT Interval in Patients with Cushing's Disease.
Topics: Adrenocorticotropic Hormone; Adult; Dose-Response Relationship, Drug; Electrocardiography; Female; H | 2016 |
Inhibition of hERG channel trafficking: an under-explored mechanism for drug-induced QT prolongation.
Topics: ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Fluoxetine; Humans; Inhibitory Concentrati | 2008 |
QT and RR intervals in conscious and anesthetized guinea pigs with highly varying RR intervals and given QTc-lengthening test articles.
Topics: Anesthesia; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cisapride; Consciousness; Electro | 2003 |
Ketoconazole induced torsades de pointes without concomitant use of QT interval-prolonging drug.
Topics: Antifungal Agents; Coronary Artery Disease; Female; Humans; Ketoconazole; Long QT Syndrome; Middle A | 2005 |
Disopyramide: although potentially life-threatening in the setting of long QT, could it be life-saving in short QT syndrome?
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Death, Sudden, Cardiac; Disopyramide; Drug Interaction | 2006 |
Interaction between ketoconazole and domperidone and the risk of QT prolongation--important safety information.
Topics: Antiemetics; Antifungal Agents; Domperidone; Drug Interactions; Humans; Ketoconazole; Long QT Syndro | 2006 |
Coexistence of hERG current block and disruption of protein trafficking in ketoconazole-induced long QT syndrome.
Topics: Antifungal Agents; Binding Sites; Blotting, Western; Cell Line; Dose-Response Relationship, Drug; El | 2008 |
Torsades de Pointes after treatment with terfenadine and ketoconazole.
Topics: Adult; Cardiac Pacing, Artificial; Dermatomycoses; Drug Therapy, Combination; Electrocardiography, A | 1992 |